July 7th 2025
New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities
View More
Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)
View More
How to Approach Severe AD With Combination Therapy
January 13th 2025A panelist discusses how combining different therapeutic approaches, such as topical agents with systemic medications, can provide optimal control for patients with severe atopic dermatitis while managing both acute flares and long-term disease maintenance.
Navigating Patient Concerns About Adverse Effects of Topicals for AD
January 13th 2025A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.
When to Choose a Systemic or Topical for Patients With Atopic Dermatitis
January 13th 2025A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.
Utilizing Safety Data When Prescribing Ruxolitinib Cream for Atopic Dermatitis
January 2nd 2025The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
Discussing Nonsteroidal Topical Creams for Atopic Dermatitis With Patients
January 2nd 2025The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.
Patient Education and Key Considerations for Initiating Topical JAK Inhibitors
December 31st 2024A panelist discusses how initiating topical JAK inhibitors requires thorough patient education about proper application techniques, safety monitoring, and setting realistic expectations for treatment response timelines.
Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis
December 31st 2024A panelist discusses how supporting patients with atopic dermatitis requires addressing both physical comorbidities and psychological health challenges simultaneously for optimal treatment outcomes.
Patient Adherence and the Future of Atopic Dermatitis Treatment
December 24th 2024James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.
Comparing and Contrasting the Current Armamentarium for Treating Atopic Dermatitis
December 24th 2024A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations.
New and Upcoming Therapies in Atopic Dermatitis
December 24th 2024James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.